Search

Displaying results 1621 - 1630 of 4246 in total
  1. Drug

    Tenecteplase

    go.drugbank.com/drugs/DB00031
    ApprovedInvestigational

    Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 1...

  2. Drug

    Trifluoperazine

    go.drugbank.com/drugs/DB00831
    Approved

    It is used as an antipsychotic and an antiemetic.

  3. Drug

    Cetirizine

    go.drugbank.com/drugs/DB00341
    ApprovedInvestigational

    Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal

  4. Drug

    Prilocaine

    go.drugbank.com/drugs/DB00750
    ApprovedInvestigational

    A local anesthetic that is similar pharmacologically to lidocaine. Currently, it is used most often for infiltration anesthesia in dentistry. (From AMA Drug Evaluations Annual, 1992, p165)

  5. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones. … It is a small molecule designed to act as a pharmacological chaperone that specifically binds, stabilizes, and facilitates the proper folding and trafficking of α-glucosidase (GAA).

  6. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    [A226305] Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead.

  7. Drug

    Phenolphthalein

    go.drugbank.com/drugs/DB04824
    ApprovedWithdrawn

    Phenolphthalein was withdrawn in Canada due to concerns with carcinogenicity in 1997.

  8. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive

  9. Drug

    Everolimus

    go.drugbank.com/drugs/DB01590
    ApprovedInvestigational

    It is currently used as an immunosuppressant to prevent rejection of organ transplants. … Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor.

  10. Drug

    Amoxicillin

    go.drugbank.com/drugs/DB01060
    ApprovedInvestigationalVet approved

    Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin. Amoxicillin was gr...

    Mixtures: Clavulin 125 F Oral Sus, Clavulin 250 F Oral SusProducts: Nu-amoxi Sus 125/5ml, Nu-amoxi Sus 250mg/5ml